How we start
To facilitate development of Taiwan’s biomedical industry, the government proposed a “biomedical industrial innovation promotion program (BIIP)” in November 2016, with the central theme of “local, global and future links” to position Taiwan as the hub of biomedical research and development (R&D) in the Asia-Pacific region. By 2025, the goal is to develop 20 new drugs and have 80 different high-value medical devices on the international market, creating an NT-trillion-dollar industry offering a wide range of quality products.
BIIP includes four action plans:
•A: to build a comprehensive ecosystem
•B: to integrate innovative business clusters
•C: to connect global market resources
•D: to promote specialized key industries
T Among them, Action A "build a comprehensive ecosystem" will be enhanced by focusing on 6 diections to proceed: personnel trainig, capital, topic selection, intellectual property, regulations, and resources. Therefore, Commercialization Center is established to consolidate resources, incubate startups, and strengthen technical support platforms for industrial and academic research.
Drug Commercialization Center, DCC, under BIIP/BDB, launches in April 2017, and is located in the Nangang National Biotechnology Research Park (NBRP).